<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; demand</title>
	<atom:link href="http://www.tapanray.in/tag/demand/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Prescription In Generic Names Only, No Branded Generics</title>
		<link>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-prescription-in-generic-names-only-no-branded-generics</link>
		<comments>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/#comments</comments>
		<pubDate>Sun, 20 Aug 2023 07:24:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[branded generics]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[IMA]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[influence]]></category>
		<category><![CDATA[lack]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10812</guid>
		<description><![CDATA[The World Bank Report released on April 07, 2023 highlights that patients&#8217; Out-of-Pocket (OoP) expenses as a percentage of their total healthcare expenditure in India still accounted for as high as 50.59%. This means that patients in India generally pay for the &#8230; <a href="http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Growing Intricacies of Today’s Field Staff Role And The Path Ahead</title>
		<link>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=growing-intricacies-of-todays-field-staff-role-and-the-path-ahead</link>
		<comments>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/#comments</comments>
		<pubDate>Mon, 30 Jan 2023 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[e-detailing]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[field. staff]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[hybridization]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intricacies]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Push]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10742</guid>
		<description><![CDATA[With a varying degree, and in various forms, a hybrid working model is now gaining greater acceptance of several top pharma companies, across the world, just as in many other industries. This trend gets echoed in an article of December 07, 2022, &#8230; <a href="http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Restart Pharma Demand Generation Activities With Actionable Insight</title>
		<link>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=restart-pharma-demand-generation-activities-with-actionable-insight</link>
		<comments>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/#comments</comments>
		<pubDate>Mon, 01 Jun 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actionable]]></category>
		<category><![CDATA[activity]]></category>
		<category><![CDATA[bedrock]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Insishr]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[restart]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Social-distancing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10107</guid>
		<description><![CDATA[As the ‘Lockdown. 04’ in India passes by, a time comes to press the restart button of all business activities in the country, in a calibrated manner, though, keeping in mind, the Covid-19 cases is yet to find its peak &#8230; <a href="http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Come Covid-19 Drug And Vaccine, Pharma Will Get Back To The Traditional Mode</title>
		<link>http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode</link>
		<comments>http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/#comments</comments>
		<pubDate>Mon, 18 May 2020 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[HiNI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[proven]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[scientifically]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[speedy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10084</guid>
		<description><![CDATA[‘Corona will remain a part of our lives for a long time. But at the same time, we cannot allow this to happen that our lives will be confined only around the corona. We would wear masks, follow two yards &#8230; <a href="http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>While Pharma Leadership Change This Atypical Skill Counts</title>
		<link>http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=while-pharma-leadership-change-this-atypical-skill-counts</link>
		<comments>http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/#comments</comments>
		<pubDate>Mon, 01 Jul 2019 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Atypical]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digital first]]></category>
		<category><![CDATA[hardware]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[software]]></category>
		<category><![CDATA[Space]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[touchpoint]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9613</guid>
		<description><![CDATA[Effective September 01, 2019, the global pharma major Sanofi will have a new CEO, as the present CEO retires attaining his retirement age of 65 years. This appears to be a mandatory announcement from the company, as is required during the &#8230; <a href="http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will ‘Patent Thicket’ Delay Biosimilar Drug Entry in India?</title>
		<link>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-patent-thicket-delay-biosimilar-drug-entry-in-india</link>
		<comments>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/#comments</comments>
		<pubDate>Mon, 22 Apr 2019 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Cyltezo]]></category>
		<category><![CDATA[delay]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[Losec]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Prilosec]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9496</guid>
		<description><![CDATA[Do pharma and biotech investors encourage companies indulging in ‘patent thicket?’ This question recently grabbed media headlines. On April 02, 2019, one such report brought out: AbbVie investors are calling for the Chair-CEO power split, flagging the CEO’s USD 4 million bonus payout, fueled &#8230; <a href="http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In VUCA World: Changing Dynamics of Prescription Generation Process</title>
		<link>http://www.tapanray.in/in-vuca-world-changing-dynamics-of-prescription-generation-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-vuca-world-changing-dynamics-of-prescription-generation-process</link>
		<comments>http://www.tapanray.in/in-vuca-world-changing-dynamics-of-prescription-generation-process/#comments</comments>
		<pubDate>Mon, 04 Nov 2013 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AHJ]]></category>
		<category><![CDATA[American]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[criticality]]></category>
		<category><![CDATA[decision]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[e-detailing]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[eluting]]></category>
		<category><![CDATA[empowerments]]></category>
		<category><![CDATA[frontline]]></category>
		<category><![CDATA[generating]]></category>
		<category><![CDATA[generation process]]></category>
		<category><![CDATA[Heart]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[interaction]]></category>
		<category><![CDATA[interfaces]]></category>
		<category><![CDATA[intervention]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Mix]]></category>
		<category><![CDATA[MRs]]></category>
		<category><![CDATA[optimal]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[stent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[tools]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[VUCA]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4051</guid>
		<description><![CDATA[The acronym VUCA is often being used to emphasize upon the Volatility, Uncertainty, Complexity and Ambiguity in various situations. The term has been derived from military vocabulary and is being used since 1990s in the business management parlance. VUCA is also &#8230; <a href="http://www.tapanray.in/in-vuca-world-changing-dynamics-of-prescription-generation-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-vuca-world-changing-dynamics-of-prescription-generation-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
